Effects of Ranolazine with Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients with Severe Chronic Angina: A Randomized Controlled Trial

JAMA

Volumn 291, Issue 3, 2004, Pages 309-316

  Chaitman, Bernard R ^a,b   Pepine, Carl J ^c   Parker, John O ^d   Skopal, Jaroslav ^e   Chumakova, Galina ^f   Kuch, Jerzy ^g   Wang, Whedy ^h   Skettino, Sandra L ^h   Wolff, Andrew A ^h  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d KINGSTON GENERAL HOSPITAL   (Canada)

^e Na Franti ku Hospital   (Czech Republic)

^f ALTAI STATE MEDICAL UNIVERSITY   (Russian Federation)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h CV THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; DILTIAZEM; GLYCERYL TRINITRATE; PLACEBO; RANOLAZINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; BLOOD PRESSURE MEASUREMENT; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL; SUSTAINED RELEASE PREPARATION; SYNCOPE; TASK PERFORMANCE; TORSADE DES POINTES; TREADMILL EXERCISE; TREATMENT OUTCOME; WORKLOAD;

EID: 0348129532     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.3.309     Document Type: Article

References (28)

1. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/ AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina. American College of Cardiology Foundation and the American Heart Association Inc; 2002. Available at: http://www.acc.org/clinical/guidelines/stable/stable.pdf. Accessibility verified December 15, 2003.
2. US Department of Health and Human Services, National Center for Health Statistics. Third National Health and Nutrition Examination Survey, (NHANES III), 1988-1994 [CD-ROM], Hyattsville, Md: Centers for Disease Control and Prevention; 1997. Series 11, No. 1, revised October 1997.
3. Pell JP, Walsh D, Norrie J, et al. Outcomes following coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in the stent era: a prospective study of all 9890 consecutive patients operated on in Scotland over a two-year period. Heart. 2001;85:662-666.
4. Serruys PW, Unger F, Sousa JE, et al, for the Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124.
5. Holubkov R, Laskey WK, Haviland A, et al, for the Registry Investigators. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J. 2002;144:826-833.
6. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol. 1996;28:341-350.
7. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93:135-142.
8. Mjos OD, Kjekshus JK, Lekven J. Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. J Clin Invest. 1974;53:1290-1299.
9. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev. 2002;7:187-203.
10. Chaitman BR, Skettino SL, Parker JO, for the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with severe chonic angina. J Am Coll Cardiol. In press.
11. Sheffield LT. Exercise stress testing. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Vol 1, 3rd ed. Philadelphia, Pa: WB Saunders Co; 1988:223-241.
12. Caralis DG, Shaw L, Bilgere B, et al. Application of computerized exercise ECG digitization: interpretation in large clinical trials. J Electrocardiol. 1992;25:101-110.
13. Gould AL, Shih WJ. "Sample size re-estimation without unblinding for normally distributed out-comes with unknown variance": communications in statistics. Theory Meth. 1992;21:2833-2853.
14. Gould AL. Planning and revising the sample size for a trial. Stat Med. 1995;14:1039-1051.
15. Kieser M, Friede T. Blinded sample size reestimation in multiarmed clinical trials. Drug Inf J. 2000;34:455-460.
16. Bauer P. Multiple testing in clinical trials. Stat Med. 1991;10:871-890.
17. Koch GG, Gansky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J. 1996;30:523-534.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Beinart SC, Sales AE, Spertus JA, Plomondon ME, Every NR, Rumsfeld JS. Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes. Am Heart J. 2003;146:646-652.
20. Boden WE, Bough EW, Reichman MJ, et al. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation. 1985;71:1197-1205.
21. Davies RF, Habibi H, Klinke WP, et al, for the Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol. 1995;25:619-625.
22. Hung J, Lamb IH, Connolly SJ, Jutzy KR, Goris ML, Schroeder JS. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. Circulation 1983;68:560-567.
23. Pehrsson SK, Ringqvist I, Ekdahl S, Kadson B, Ulvenstam G, Persson S. Monotherapy with amlodipine or atenolol vs their combination in stable angina pectoris. Clin Cardiol. 2000;23:763-770.
24. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, for the TIBET Study Group. The Total Ischaemic Burden European Trial (TIBET): effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J. 1996;17:96-103.
25. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20:131-138.
26. Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de points in the canine left ventricular wedge preparation during epicardial stimulation. Circulation. 2003;108:1027-1033.
27. Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 1987;106:793-800.
28. Alexander KP, Shaw U, Shaw LK, Delong ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women. J Am Coll Cardiol. 1998;32:1657-1664.